Kimberly Showalter1, Laura C Pinheiro2, Deanna Jannat-Khah1, Irina Sobol3, Jackie Szymonifka1, Jackie Finik1, Virginia D Steen4, Jessica K Gordon1. 1. Department of Medicine, Division of Rheumatology, Hospital for Special Surgery. 2. Department of Medicine, Division of General Internal Medicine, Weill Cornell Medicine. 3. Department of Medicine, Division of Cardiology, Weill Cornell Medicine. 4. Department of Medicine, Division of Rheumatology, MedStar Georgetown University Hospital, Washington DC, USA.
Abstract
OBJECTIVE: To identify individual-level factors associated with hospital readmission among individuals with SSc-associated pulmonary hypertension (SSc-PH). METHODS: Individuals enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry contributed clinical data related to SSc-PH disease severity and hospital admissions. Readmission was defined as a subsequent hospitalization within 12 months of any hospital discharge. Characteristics were compared between individuals with and without readmissions using Fisher's exact test, Wilcoxon rank-sum test, or Kruskal-Wallis test. Logistic regression was used to estimate associations between clinical predictors and likelihood of readmission. RESULTS: Of 572 individuals with SSc-PH enrolled in PHAROS, 54% had ≥1 hospitalizations between 2005 and 2016. Among individuals ever-hospitalized, 34% had ≥1 readmission. Individuals with vs without readmissions had shorter median (IQR) time between index hospitalization date and next PHAROS visit [37 (3, 80) vs 81 (42, 136) days, P <0.001]. Index admissions related to PH or SSc (vs non-PH/SSc related) were associated with an increased odds of 12-month readmission [aOR 6.6 (95% CI 3.2, 13.6) and aOR 2.2 (95% CI 1.1, 4.5), respectively]. Readmission was less likely among home oxygen users (vs non-users) (aOR 0.44; 95% CI 0.22, 0.89). Race, age, sex, disease duration and disease subtype were not associated with readmission. CONCLUSION: The strongest predictor for 12-month readmission was an index hospitalization reason related to PH. Home oxygen use was associated with lower odds of readmission. Future studies should determine whether testing for the need for home oxygen mediates the risk of readmission in SSc-PH.
OBJECTIVE: To identify individual-level factors associated with hospital readmission among individuals with SSc-associated pulmonary hypertension (SSc-PH). METHODS: Individuals enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry contributed clinical data related to SSc-PH disease severity and hospital admissions. Readmission was defined as a subsequent hospitalization within 12 months of any hospital discharge. Characteristics were compared between individuals with and without readmissions using Fisher's exact test, Wilcoxon rank-sum test, or Kruskal-Wallis test. Logistic regression was used to estimate associations between clinical predictors and likelihood of readmission. RESULTS: Of 572 individuals with SSc-PH enrolled in PHAROS, 54% had ≥1 hospitalizations between 2005 and 2016. Among individuals ever-hospitalized, 34% had ≥1 readmission. Individuals with vs without readmissions had shorter median (IQR) time between index hospitalization date and next PHAROS visit [37 (3, 80) vs 81 (42, 136) days, P <0.001]. Index admissions related to PH or SSc (vs non-PH/SSc related) were associated with an increased odds of 12-month readmission [aOR 6.6 (95% CI 3.2, 13.6) and aOR 2.2 (95% CI 1.1, 4.5), respectively]. Readmission was less likely among home oxygen users (vs non-users) (aOR 0.44; 95% CI 0.22, 0.89). Race, age, sex, disease duration and disease subtype were not associated with readmission. CONCLUSION: The strongest predictor for 12-month readmission was an index hospitalization reason related to PH. Home oxygen use was associated with lower odds of readmission. Future studies should determine whether testing for the need for home oxygen mediates the risk of readmission in SSc-PH.
Authors: Gerald Simonneau; Nazzareno Galiè; Lewis J Rubin; David Langleben; Werner Seeger; Guido Domenighetti; Simon Gibbs; Didier Lebrec; Rudolf Speich; Maurice Beghetti; Stuart Rich; Alfred Fishman Journal: J Am Coll Cardiol Date: 2004-06-16 Impact factor: 24.094
Authors: Guillaume Lefèvre; Luc Dauchet; Eric Hachulla; David Montani; Vincent Sobanski; Marc Lambert; Pierre-Yves Hatron; Marc Humbert; David Launay Journal: Arthritis Rheum Date: 2013-09
Authors: Vivien M Hsu; Lorinda Chung; Laura K Hummers; Fredrick Wigley; Robert Simms; Marcy Bolster; Rick Silver; Aryeh Fischer; Monique E Hinchcliff; John Varga; Avram Z Goldberg; Chris T Derk; Elena Schiopu; Dinesh Khanna; Lee S Shapiro; Robyn T Domsic; Thomas Medsger; Maureen D Mayes; Daniel Furst; Mary E Csuka; Jerry A Molitor; Firas Alkassab; Virginia D Steen Journal: Semin Arthritis Rheum Date: 2014-03-05 Impact factor: 5.532
Authors: Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Caitrin M Coffey; Avneek S Sandhu; Cynthia S Crowson; Sara J Achenbach; Eric L Matteson; Thomas G Osborn; Kenneth J Warrington; Ashima Makol Journal: J Rheumatol Date: 2020-11-15 Impact factor: 5.346